Drug Profile

Tamoxifen vaginal - Dare Bioscience

Alternative Names: DARE VVA1; PT 101

Latest Information Update: 08 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pear Tree Pharmaceuticals
Developer Dare Bioscience
Class Antineoplastics; Chemopreventatives; Dimethylamines; Infertility therapies; Phenyl ethers; Small molecules; Stilbenes
Mechanism of Action Estrogen receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Atrophic vaginitis

Most Recent Events

05 Apr 2024 Dare Bioscience has a povisional patent pending for tamoxifen in USA
07 Dec 2023 US FDA approves IND application for Tamoxifen vaginal in Atrophic vaginitis
11 May 2023 Dare Bioscience announces intention to submit IND application to regulatory body for Atrophic vaginitis in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com